Yazan F. Madanat

<i>TP53</i> mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML

Olga K. Weinberg, Alexa J. Siddon, Yazan F. Madanat et al. · Blood Advances · 2022 · 175 citations · Full text

NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022

Peter L. Greenberg, Richard M. Stone, Aref Al‐Kali et al. · Journal of the National Comprehensive Cancer Network · 2022 · 121 citations · Full text

Hematological Malignancy, Family Medicine, Nccn Guidelines® Insights +15

Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

Aaron T. Gerds, Jason Gotlib, Haris Ali et al. · Journal of the National Comprehensive Cancer Network · 2022 · 119 citations · Full text

Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial

Uwe Platzbecker, Valeria Santini, Pierre Fenaux et al. · The Lancet · 2023 · 118 citations

Hematological Malignancy, Thrombosis, Erythropoiesis-stimulating Agents +9

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

Naveen Pemmaraju, Hagop M. Kantarjian, Kendra Sweet et al. · Blood · 2022 · 54 citations · Full text